^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ACE2016

    i
    Other names: ACE2016, ACE-2016, ACE 2016
    Company:
    Acepodia
    Drug class:
    EGFR inhibitor, γδ TCR modulator
    Related drugs:
    6ms
    ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Acepodia Biotech, Inc.
    New P1 trial • Metastases
    |
    IL2 (Interleukin 2)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • ACE2016
    over1year
    ACE2016: an off-the-shelf EGFR-targeting γδ2 T cell therapy against EGFR-expressing solid tumors (AACR 2023)
    ACE2016, an EGFR-targeting γδ2 T cell product, was successfully generated as an effective off-the-shelf treatment for EGFR-expressing solid tumors. This study provides the evidence for the in vitro and in vivo efficacy of ACE2016 against EGFR-expressing cancer cells to support the clinical application against EGFR-expressing tumors.
    Late-breaking abstract
    |
    IL6 (Interleukin 6)
    |
    EGFR expression • EGFR negative
    |
    ACE2016